SAGE Therapeutics Inc (OQ:SAGE)

Business Focus: Biotechnology & Medical Research

Mar 18, 2020 06:30 am ET
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced next steps in the Landscape Program, the clinical program evaluating zuranolone (SAGE-217) for the treatment of postpartum depression (PPD) and major depressive disorder (MDD), following a Breakthrough Therapy guidance meeting with the U.S. Food and Drug Administration (FDA). Sage has identified three potential pathways intended, if successful, to support a possible filing for ap
Mar 11, 2020 07:00 am ET
Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida...
Mar 04, 2020 04:30 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on March 2, 2020, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 4,500 shares of its common stock, and 750 performance restricted stock units (PSUs) to 1 new employee under Sage’s 2016 Inducement Equity Plan.
Feb 27, 2020 07:39 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud
Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors with losses in excess of $100,000 to submit their losses now to learn if they qualify to recover compensable damages.       Relevant Holding Period: Before Feb. 27, 2020Sign Up:...
Feb 27, 2020 06:30 am ET
Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress
Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.
Feb 24, 2020 06:30 am ET
Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Cowen & Co. 40th Annual Health Care Conference on Monday, March 2, 2020, at 12:00 p.m. EST in Boston, Mass.
Feb 10, 2020 06:30 am ET
Sage Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, February 27, 2020 at 8:00 a.m. EST to report its fourth quarter and full year 2019 financial results and discuss recent business updates.
Feb 04, 2020 04:30 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, February 3, 2020, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 13,950 shares of its common stock, and 6,325 performance restricted stock units (PSUs) to four new employees under Sage’s 2016 Inducement Equity Plan.
Jan 03, 2020 04:30 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Thursday, January 2, 2020, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 11,850 shares of its common stock, and 1,975 performance restricted stock units (PSUs) to four new employees under Sage’s 2016 Inducement Equity Plan.
Dec 23, 2019 06:30 am ET
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the J.P. Morgan 2020 Healthcare Conference in San Francisco, Calif. on Monday, January 13, 2020 at 1:30 p.m. PST (4:30 p.m. EST), followed by a Q&A session.
Dec 11, 2019 08:01 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened
Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who have suffered losses in excess of $100,000 on purchases prior to December 5, 2019 to submit their losses now to learn if they qualify to recover compensable damages.  The firm...
Dec 10, 2019 07:30 am ET
Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it plans to advance SAGE-718, a novel, first-in-class, oxysterol-based positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors, to a Phase 2 placebo-controlled clinical trial in patients with Huntington’s disease (HD). The planned progression of SAGE-718 is based on results from Phase 1 studies evaluating the safety and tolerability of SAGE-718, including an o
Dec 05, 2019 08:31 pm ET
Lost Money in Sage Therapeutics, Inc.?
Sage Therapeutics, Inc. shares plummeted 60% after the company announced that its depression drug, SAGE-217, failed to perform better than a placebo in its Phase 3 trial. Gibbs Law Group is investigating a potential Sage Therapeutics Class Action Lawsuit on behalf of investors
Dec 05, 2019 06:30 am ET
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel therapies for people with debilitating brain disorders, today reported topline results from the pivotal Phase 3 MOUNTAIN Study evaluating the effect of SAGE-217 on depressive symptoms in adults with major depressive disorder (MDD). The MOUNTAIN Study did not meet its primary endpoint of a statistically significant reduction from baseline compared to placebo in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score at Day 15. SAGE-217 30 mg, given once-daily as an oral treatment, was associated with a m
Dec 03, 2019 04:30 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, December 2, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 4,200 shares of its common stock, and 700 performance restricted stock units (PSUs) to two new employees under Sage’s 2016 Inducement Equity Plan.
Nov 25, 2019 06:44 pm ET
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE) breached their fiduciary duties to shareholders. Sage Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes medicines to treat central nervous system (CNS) di
Nov 12, 2019 06:31 am ET
Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
Today, Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the third quarter ended September 30, 2019.
Nov 11, 2019 04:30 pm ET
Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019, at 10:20 a.m. EST in New York, NY.
Nov 05, 2019 06:00 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on November 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 7,350 shares of its common stock, and 1,225 performance restricted stock units (PSUs) to three new employees under Sage’s 2016 Inducement Equity Plan.
Oct 30, 2019 01:49 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Sage Therapeutics, Inc.- SAGE
Levi & Korsinsky announces it has commenced an investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/SAGE-Info-Request-Form-7470...
Oct 09, 2019 06:30 am ET
Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Tuesday, November 12, 2019 at 8:00 a.m. EST to report its third quarter 2019 financial results and discuss recent business updates.
Oct 02, 2019 04:30 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on October 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 8,100 shares of its common stock, and 1,350 performance restricted stock units (PSUs) to four new employees under Sage’s 2016 Inducement Equity Plan.
Oct 02, 2019 06:30 am ET
Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in an Executive Conference Call Series hosted by J.P. Morgan on Thursday, October 3, 2019 at 10:00 AM EDT.
Sep 05, 2019 04:31 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on September 3, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 12,300 shares of its common stock, and 2,050 performance restricted stock units (PSUs) to four new employees under Sage’s 2016 Inducement Equity Plan.
Sep 04, 2019 05:05 pm ET
Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that the New England Journal of Medicine (NEJM) published full results from the double-blind, randomi
Sep 03, 2019 05:31 pm ET
Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 11:05 a.m. EDT in New York, NY.
Aug 06, 2019 06:30 am ET
Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
Today, Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the second quarter ended June 30, 2019.
Aug 05, 2019 04:30 pm ET
Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, in New York, NY.
Aug 05, 2019 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on August 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 11,550 shares of its common stock, and 1,925 performance restricted stock units (PSUs) to seven new employees under Sage’s 2016 Inducement Equity Plan.
Jul 24, 2019 06:30 am ET
Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast”
Today, Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, will host “Sage FutureCast: An R&D Portfolio Review” and report clinical progress in select depression, neurology, and neuropsychiatry franchise programs.
Jul 11, 2019 06:30 am ET
Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.m. EDT to report its second quarter 2019 financial results and discuss recent business updates.
Jul 03, 2019 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 14,700 shares of its common stock, and 4,450 performance restricted stock units (PSUs) to six new employees under Sage’s 2016 Inducement Equity Plan.
Jun 27, 2019 06:30 am ET
Sage Therapeutics to Host “Sage FutureCast” Webcast
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host “Sage FutureCast: An R&D and Portfolio Review” on Wednesday, July 24, 2019 from 8 a.m. to 9:30 a.m. EDT.
Jun 18, 2019 06:30 am ET
Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 8:40 a.m. EST in New York, NY.
Jun 14, 2019 08:53 am ET
Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Drug Enforcement Administration (DEA) has placed ZULRESSO™ (brexanolone) injection into Schedule IV of the Controlled Substances Act. ZULRESSO, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, is the first and only treatment specifically approved for postpartum depression (PPD), the most common medical complication of childbirth.
Jun 05, 2019 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 4,200 shares of its common stock, and 700 performance restricted stock units (PSUs) to two new employees under Sage’s 2016 Inducement Equity Plan.
Jun 04, 2019 06:30 am ET
Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 8:00 a.m. PDT (11:00 a.m. EDT) in Palos Verdes, Cal.
May 23, 2019 09:06 am ET
Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.D., initiates coverage on six stocks in the Healthcare and BioTech space. Initiations are on the following: Acer Therapeutics Inc. (ACER), Acorda Therapeutics, Inc. (ACOR), Alexion Pharmaceuticals (ALXN), Biogen Inc (BIIB), Dova Pharmaceuticals, Inc. (DOVA), and Sage Therapeutics, Inc. (SAGE).  ...
May 14, 2019 06:30 am ET
Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019 at 3:35 p.m. EDT in New York, NY.
May 07, 2019 04:01 pm ET
Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 8:40 a.m. PDT (11:40 a.m. EDT) in Las Vegas, Nev.
May 06, 2019 04:45 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 21,680 shares of its common stock, and 6,280 performance restricted stock units (PSUs) to six new employees under Sage’s 2016 Inducement Equity Plan.
May 02, 2019 06:30 am ET
Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2019.
Apr 29, 2019 10:47 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Sage Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Sage Therapeutics, Inc. (NASDAQGM: SAGE) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/SAGE-Info-Request-Form-7470...
Apr 18, 2019 04:30 pm ET
Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 2, 2019 at 8:00 A.M. ET to report its first quarter 2019 financial results and to discuss recent business updates.
Apr 03, 2019 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 25,190 shares of its common stock, and 865 performance restricted stock units (PSUs) to five new employees under Sage’s 2016 Inducement Equity Plan.
Mar 19, 2019 07:00 pm ET
Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced today the U.S. Food and Drug Administration (FDA) has approved ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth. ZULRESSO is expected to be available in late June following scheduling by the U.S. Drug Enforcement Ad
Mar 05, 2019 07:20 am ET
Market Trends Toward New Normal in Macy's, Comerica, JetBlue Airways, Intersect ENT, Stanley Black & Decker, and Sage Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Macy's, Inc. (NYSE:M), Comerica Incorporated (NYSE:CMA), JetBlue Airways...
Mar 05, 2019 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 12,550 shares of its common stock, and 4,025 performance restricted stock units (PSUs) to three new employees under Sage’s 2016 Inducement Equity Plan.
Feb 27, 2019 04:01 pm ET
Sage Therapeutics Announces Closing of $575 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 500,000 shares at the public offering price of $150.00 per share, less the underwriting discount. The exercise of the option to purchase additional shares brought the total number of shares
Feb 25, 2019 09:05 pm ET
Sage Therapeutics Prices Public Offering of Common Stock
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $150.00 per share. The gross proceeds to Sage Therapeutics from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $500 million. The offering is expected to
Feb 25, 2019 04:01 pm ET
Sage Therapeutics Announces Proposed Public Offering of Common Stock
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock. Sage also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of its common stock offered in the public offering. All shares in the offering are to be sold by Sage.
Feb 19, 2019 06:30 am ET
Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.
Feb 08, 2019 07:50 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within New Relic, Clean Harbors, Sage Therapeutics, Accelerate Diagnostics, Fortinet, and Colfax — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of New Relic, Inc. (NYSE:NEWR), Clean Harbors, Inc. (NYSE:CLH), Sage...
Feb 07, 2019 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 8,500 shares of its common stock, and 750 performance restricted stock units (PSUs) to two new employees under Sage’s 2016 Inducement Equity Plan.
Feb 05, 2019 06:30 am ET
Sage Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 19, 2019
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, February 19, 2019 at 8:00 a.m. EST to report its fourth quarter and full year 2018 financial results and to discuss recent business updates.
Jan 24, 2019 09:00 am ET
Three Companies Using AI and Innovation to Lead Healthcare Sector
HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence.
Jan 23, 2019 07:00 am ET
Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company’s board of directors.
Jan 07, 2019 07:35 am ET
Report: Developing Opportunities within General Mills, Philip Morris International, Sage Therapeutics, CNA Financial, Hess, and AutoNation — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of General Mills, Inc. (NYSE:GIS), Philip Morris International Inc....
Jan 07, 2019 07:00 am ET
Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference
Sage Therapeutics, Inc. (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer, Jeff Jonas, M.D., will discuss the Company’s progress as a leading, multi-franchise CNS company in a corporate presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. As part of the presentation, Dr. Jonas will highlight key programs in the expanding portfolio of product candidates across Sage’s d
Jan 07, 2019 06:00 am ET
Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient treatment, patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (
Jan 04, 2019 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to five new employees under Sage’s 2016 Inducement Equity Plan.
Dec 27, 2018 06:30 am ET
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the J.P. Morgan 2019 Healthcare Conference in San Francisco, Calif. on Tuesday, January 8, 2019 at 3:30 p.m. PST (6:30 p.m. EST), followed by a Q&A session.
Dec 05, 2018 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 156,100 shares of its common stock to 93 new employees under Sage’s 2016 Inducement Equity Plan.
Nov 29, 2018 07:45 am ET
New Research: Key Drivers of Growth for Upland Software, VICI Properties, Sage Therapeutics, Jack Henry & Associates, T2 Biosystems, and Tata Motors — Factors of Influence, Major Initiatives and Susta
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Upland Software, Inc. (NASDAQ:UPLD), VICI Properties Inc. (NYSE:VICI),...
Nov 21, 2018 06:30 am ET
Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018 at 09:30 A.M. ET in New York, NY.
Nov 20, 2018 07:30 am ET
Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO™ (brexanolone) Injection
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the New Drug Application (NDA) for ZULRESSO™ (brexanolone) injection for the treatment of postpartum depression (PPD). The previously disclosed December 19, 2018 PDUFA goal date has been extended by a period of three m
Nov 07, 2018 04:01 pm ET
Sage Therapeutics to Present at Stifel 2018 Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 09:30 A.M. ET in New York, NY.
Nov 06, 2018 06:30 am ET
Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the third quarter ended September 30, 2018.
Nov 05, 2018 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,400 shares of its common stock to 12 new employees under Sage’s 2016 Inducement Equity Plan.
Nov 02, 2018 04:45 pm ET
Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) jointly voted (17 yes, 1 no) that data support the favorable benefit-risk profile of ZULRESSO™ (brexanolone) injection for the treatment of postpartum depression (PPD) when administered by qualified
Nov 02, 2018 07:00 am ET
Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) are holding a joint meeting today (scheduled from 8:00 A.M. to 5:00 P.M. ET) to discuss Sage’s New Drug Application (NDA) currently under review fo
Oct 23, 2018 06:30 am ET
Sage Therapeutics to Report Third Quarter 2018 Financial Results on Tuesday, November 6, 2018
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 6, 2018 at 8:00 A.M. ET to report its third quarter 2018 financial results and to discuss recent business updates.
Oct 19, 2018 07:55 am ET
Detailed Research: Economic Perspectives on W.W. Grainger, Jabil, Grand Canyon Education, Sage Therapeutics, H. B. Fuller, and Jazz Pharmaceuticals — What Drives Growth in Today's Competitive Landscap
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of W.W. Grainger, Inc. (NYSE:GWW), Jabil, Inc. (NYSE:JBL), Grand Canyon...
Oct 03, 2018 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 79,600 shares of its common stock to 11 new employees under Sage’s 2016 Inducement Equity Plan.
Sep 06, 2018 04:05 pm ET
Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018 at 01:40 P.M. ET in New York, NY.
Sep 06, 2018 06:30 am ET
Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 145,000 shares of its common stock to 63 new employees under Sage’s 2016 Inducement Equity Plan.
Aug 31, 2018 06:40 pm ET
Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced The Lancet has published an integrated analysis across three, double-blind, randomized, placebo-controlled studies of brexanolone injectio
Aug 03, 2018 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 93,600 shares of its common stock to 16 new employees under Sage’s 2016 Inducement Equity Plan.
Aug 01, 2018 06:30 am ET
Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual Growth Conference on Wednesday, August 8, 2018 at 11:00 A.M. ET in Boston, MA.
Jul 24, 2018 06:30 am ET
Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 7, 2018 at 8:00 A.M. ET to report its second quarter 2018 financial results and to discuss recent business updates.
Jul 05, 2018 04:01 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 129,000 shares of its common stock to 31 new employees under Sage’s 2016 Inducement Equity Plan.
Jun 25, 2018 07:35 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, June 25, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sage Therapeutics, Inc. (NASDAQ: SAGE). ...
Jun 13, 2018 09:33 pm ET
Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in
Jun 12, 2018 07:55 am ET
Market Trends Toward New Normal in Cheniere Energy Partners, LP, UnitedHealth Group, Anthem, Sage Therapeutics, Harris, and A-Mark Precious Metals — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cheniere Energy Partners, LP (NYSE:CQP), UnitedHealth Group Incorporated...
Jun 12, 2018 06:30 am ET
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA). This development plan is intended to support a potential filing for approval of SAGE-217 in the U.S. for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Jun 08, 2018 07:00 am ET
Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 9:20 A.M. PT (12:20 P.M. ET) in Rancho Palos Verdes, CA.
Jun 04, 2018 04:05 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 59,600 shares of its common stock to eleven new employees under Sage’s 2016 Inducement Equity Plan.
May 30, 2018 07:00 am ET
Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for Sage’s lead product candidate, an intravenous formulation of brexanolone (SAGE-547) for the treatment of postpartum depression (PPD). The NDA was granted Priority Review status and the FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of
May 23, 2018 06:30 am ET
Sage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at Bernstein’s 34th Annual Strategic Decisions Conference on Wednesday, May 30, 2018 at 11:00 A.M. ET in New York, NY.
May 08, 2018 06:30 am ET
Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that members of the Sage management team will participate in a fireside chat presentation at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 at 3:40 P.M. PT (6:40 P.M. ET) in Las Vegas, Nev.
May 03, 2018 04:01 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 156,000 shares of its common stock to fourteen new employees under Sage’s 2016 Inducement Equity Plan.
May 03, 2018 06:30 am ET
Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2018.
Apr 24, 2018 06:30 am ET
Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 3, 2018 at 8:00 A.M. ET to report its first quarter 2018 financial results and to discuss recent business updates.
Apr 23, 2018 07:00 am ET
Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, an intravenous formulation of brexanolone (SAGE-547), for the treatment of postpartum depression (PPD).
Apr 17, 2018 04:01 pm ET
Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
Sage Therapeutics (NASDAQ: SAGE) a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that data from clinical studies of its proprietary i.v. formulation of brexanolone for the treatment of postpartum depression (PPD) as well as SAGE-217, its novel, next-generation positive allosteric modulator of synaptic and extrasynaptic GABAA receptors, in major depressive disorder (MDD), will be presented in podium and poster sessions at the following
Apr 04, 2018 04:01 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 162,000 shares of its common stock to twenty new employees under Sage’s 2016 Inducement Equity Plan.
Mar 05, 2018 04:01 pm ET
Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at the Cowen & Co. 38th Annual Health Care Conference on Monday, March 12, 2018 at 2:50 P.M. ET in Boston.
Mar 05, 2018 06:30 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 48,000 shares of its common stock to eight new employees under Sage’s 2016 Inducement Equity Plan.
Feb 22, 2018 06:30 am ET
Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017.
Feb 22, 2018 06:00 am ET
SAGE Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 8:00 AM Eastern Time.
Feb 20, 2018 08:20 am ET
Research Report Identifies Advanced Disposal Services, Opus Bank, Anworth Mortgage Asset, Exelon, Newell Brands, and Sage Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward
NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advanced Disposal Services Inc. (NYSE:ADSW), Opus...
Feb 13, 2018 06:30 am ET
Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, February 22, 2018 at 8:00 A.M. ET to report its fourth quarter and full year 2017 financial results and to discuss recent business updates.
Feb 12, 2018 04:01 pm ET
Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 1:30 P.M. ET in New York.
Feb 08, 2018 10:14 pm ET
Sage Therapeutics Prices Public Offering of Common Stock
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,506,098 shares of its common stock at a public offering price of $164.00 per share. The gross proceeds to Sage Therapeutics from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $575.0 million. The offering is expected t
Feb 07, 2018 04:01 pm ET
Sage Therapeutics Announces Proposed Public Offering of Common Stock
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $575.0 million of its common stock. Sage also intends to grant the underwriters a 30-day option to purchase up to an additional $86.3 million of its common stock offered in the public offering. All of the shares in the offering are to be sold by Sage.
Feb 07, 2018 06:30 am ET
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SAGE-217 for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation granted to Sage since 2016.
Feb 02, 2018 04:01 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 113,000 shares of its common stock to sixteen new employees under Sage’s 2016 Inducement Equity Plan.
Jan 31, 2018 06:00 am ET
Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatme
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive results from a Phase 1/2, double-blind, placebo-controlled study of SAGE-217 in the treatment of healthy adult volunteers using a 5-hour phase advance model of insomnia using polysomnography. SAGE-217, administered as a single dose at either 30 or 45 mg, significantly improved sleep efficiency (SE), the primary endpoint of the trial, to a median of 85 perce
Jan 08, 2018 07:00 am ET
Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Compa
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that in a corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, the Company’s Chief Executive Officer, Jeff Jonas, M.D., will discuss several components of the Company’s strategy to build the business for the long term by assembling the capabilities to fully develop and commercialize important medicines. His remarks
Jan 03, 2018 04:15 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 144,800 shares of its common stock to fifteen new employees under Sage’s 2016 Inducement Equity Plan.
Jan 02, 2018 04:30 pm ET
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company is scheduled to present at the J.P. Morgan 2018 Healthcare Conference in San Francisco on Tuesday, January 9, 2018 at 11:30 a.m. PT (2:30 p.m. ET), followed by a Q&A session.
Dec 07, 2017 05:02 pm ET
Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at the BMO Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 1:30 P.M. ET in New York.
Dec 07, 2017 06:00 am ET
Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive top-line results from the Phase 2, double-blind, placebo-controlled clinical trial of SAGE-217 in the treatment of 89 adult patients with moderate to severe major depressive disorder (MDD). In the trial, treatment for 14 days with SAGE-217 was associated with a statistically significant mean reduction in the Hamilton Rating Scale for Depression (HAM-D) 17-I
Dec 04, 2017 04:01 pm ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 1, 2017, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 98,000 shares of its common stock to eight new employees under Sage’s 2016 Inducement Equity Plan.
Dec 04, 2017 08:05 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Exelon, Newell Brands, Sage Therapeutics, Advanced Disposal Services, Opus Bank, and Anworth Mortgage Asset — New Research Emphasize
NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Exelon Corporation (NYSE:EXC), Newell Brands...
Nov 17, 2017 04:01 pm ET
Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 529,411 shares at the public offering price of $85.00 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Sage
Nov 14, 2017 09:00 pm ET
Sage Therapeutics Prices Public Offering of Common Stock
Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,529,411 shares of its common stock at a public offering price of $85.00 per share. The gross proceeds to Sage Therapeutics from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $300.0 million. The offering is expected t
Nov 13, 2017 04:01 pm ET
Sage Therapeutics Announces Proposed Public Offering of Common Stock
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $300.0 million of its common stock. Sage also intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of its common stock offered in the public offering. All the shares in the offering are to be sold by Sage.
Nov 09, 2017 06:00 am ET
Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive top-line results from two Phase 3 clinical trials with its proprietary i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 202B in severe postpartum depression (PPD) and Study 202C in moderate PPD. Brexanolone achieved the primary endpoint in both trials, a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D)
Nov 08, 2017 07:00 am ET
Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Asha Nayak, M.D., Ph.D., chief medical officer for a multinational technology company, to the company’s board of directors.
Nov 06, 2017 07:50 am ET
Report: Developing Opportunities within Abaxis, PRA Health Sciences, Brighthouse, Investors Bancorp, Cypress Semiconductor, and Sage Therapeutics – Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abaxis, Inc. (NASDAQ:ABAX), PRA Health Sciences,...
Nov 03, 2017 07:00 am ET
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on November 1, 2017, the Compensation Committee of Sage’s Board of Directors granted a non-qualified stock option to purchase 6,000 shares of its common stock to one new employee under Sage’s 2016 Inducement Equity Plan.
Nov 02, 2017 06:30 am ET
Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the third quarter ended September 30, 2017.
Oct 24, 2017 08:00 am ET
Sage Therapeutics to Report Third Quarter 2017 Financial Results on Thursday, November 2, 2017
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, November 2, 2017 at 8:00 am ET to report its third quarter 2017 financial results and to discuss recent business updates.
Apr 03, 2017 09:00 am ET
Pershing Gold to Present at 2017 European Gold Forum
LAKEWOOD, Colo., April 3, 2017 /CNW/ -- Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) ("Pershing Gold" or the "Company"), the emerging Nevada gold producer advancing the Relief Canyon Mine, today announced that Stephen Alfers ("Alfers"), Pershing Gold's Executive Chairman, CEO and President, will present at the 2017 European Gold Forum. ...
Apr 03, 2017 09:00 am ET
Pershing Gold to Present at 2017 European Gold Forum
LAKEWOOD, Colo., April 3, 2017 /PRNewswire/ -- Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) ("Pershing Gold" or the "Company"), the emerging Nevada gold producer advancing the Relief Canyon Mine, today announced that Stephen Alfers ("Alfers"), Pershing Gold's Executive Chairman, CEO and President, will present at the 2017 European Gold Forum. ...
Mar 03, 2017 09:41 am ET
Mar 23, 2016 07:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Sage Therapeutics, Inc. - SAGE
NEW YORK, March 23, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Mar 23, 2016 04:44 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sage Therapeutics, Inc. (SAGE)
NEW YORK, March 23, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ: SAGE). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. ...